Immunic
PublicImmunic is now publicly traded
The data on this page reflects Immunic's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Post-IPO Financing
Feb 17, 2026
Total Funding Raised
$260M
Company Overview
Immunic has raised $260M. It was founded in 2016.
Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.
AI Layer
Non-AI
Immunic Comparables
Compare Immunic with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Artax Biopharma | 62% | |
| PharmassêtX Inc. | 49% | |
| Nemysis Limited | 43% |
For institutional investors. Book with your work email.
Immunic Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Post-IPO Financing | Feb 17, 2026 | ||||
| Private Placement | Oct 10, 2022 |
For institutional investors. Book with your work email.
Immunic Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Post-IPO Financing |
| Janus Henderson Group | Post-IPO Financing |
| RA Capital Management | Post-IPO Financing |
| TCG Crossover | Post-IPO Financing |
| Coastlands Capital LP | Post-IPO Financing |
| OrbiMed | Post-IPO Financing |
| BVF Partners L.P. | Post-IPO Financing |
For institutional investors. Book with your work email.
Immunic Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.